IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Massmutual Trust Co. FSB ADV

Massmutual Trust Co. FSB ADV lifted its holdings in IQVIA Holdings Inc. (NYSE:IQVGet Rating) by 42.9% during the second quarter, Holdings Channel reports. The fund owned 300 shares of the medical research company’s stock after buying an additional 90 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in IQVIA were worth $65,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in IQV. JPMorgan Chase & Co. boosted its holdings in IQVIA by 29.4% during the fourth quarter. JPMorgan Chase & Co. now owns 313,130 shares of the medical research company’s stock worth $88,345,000 after buying an additional 71,052 shares in the last quarter. Invesco Ltd. boosted its holdings in IQVIA by 5.6% during the fourth quarter. Invesco Ltd. now owns 2,488,845 shares of the medical research company’s stock worth $702,201,000 after buying an additional 132,455 shares in the last quarter. Clark Capital Management Group Inc. lifted its holdings in IQVIA by 3.3% during the fourth quarter. Clark Capital Management Group Inc. now owns 108,168 shares of the medical research company’s stock valued at $30,519,000 after purchasing an additional 3,505 shares in the last quarter. Glassman Wealth Services lifted its holdings in IQVIA by 23.1% during the fourth quarter. Glassman Wealth Services now owns 277 shares of the medical research company’s stock valued at $78,000 after purchasing an additional 52 shares in the last quarter. Finally, Rockefeller Capital Management L.P. lifted its holdings in IQVIA by 12.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 7,945 shares of the medical research company’s stock valued at $2,240,000 after purchasing an additional 875 shares in the last quarter. 86.77% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of IQV opened at $203.70 on Tuesday. IQVIA Holdings Inc. has a 1-year low of $194.67 and a 1-year high of $285.61. The stock has a market cap of $37.99 billion, a PE ratio of 34.01, a P/E/G ratio of 1.87 and a beta of 1.34. The firm has a 50-day simple moving average of $224.94 and a two-hundred day simple moving average of $220.73. The company has a debt-to-equity ratio of 2.36, a current ratio of 0.96 and a quick ratio of 0.96.

IQVIA (NYSE:IQVGet Rating) last posted its quarterly earnings data on Thursday, July 21st. The medical research company reported $2.44 EPS for the quarter, beating the consensus estimate of $2.22 by $0.22. IQVIA had a net margin of 8.21% and a return on equity of 30.21%. The business had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.49 billion. During the same quarter last year, the firm posted $1.94 earnings per share. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. As a group, analysts forecast that IQVIA Holdings Inc. will post 9.4 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on IQV shares. Barclays decreased their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, September 12th. Guggenheim increased their target price on shares of IQVIA to $246.00 in a research report on Friday, July 22nd. SVB Leerink started coverage on shares of IQVIA in a research report on Friday, July 15th. They issued an “outperform” rating and a $256.00 target price for the company. Credit Suisse Group started coverage on shares of IQVIA in a research report on Wednesday, August 24th. They issued an “outperform” rating and a $300.00 target price for the company. Finally, Robert W. Baird increased their target price on shares of IQVIA from $260.00 to $265.00 in a research report on Friday, July 22nd. Two research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $275.00.

IQVIA Profile

(Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVGet Rating).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.